Cha Biotech Invests 55.25 Billion KRW in New Facility Expansion

[Asia Economy Reporter Lee Jung-yoon] Cha Biotech announced on the 20th that it has decided to invest 55.25 billion KRW in a new CDMO GMP facility.

This amount corresponds to 7.62% of the company's equity capital, and the investment period is until December 1, 2024. The company stated, "This is for the establishment of a global cell and gene therapy CDMO production facility and biobank."